Efficacy and safety of eltrombopag combined with immunosuppressive therapy in the treatment of severe aplastic anemia：a meta-analysis

LI Biyun; HAN Yahui; YIN Chuyun; DU Weichuang; LI Yuanfang; WANG Dao

doi:10.6039/j.issn.1001-0408.2023.15.19

您当前的位置：

首页 >

文章列表页 >

Efficacy and safety of eltrombopag combined with immunosuppressive therapy in the treatment of severe aplastic anemia：a meta-analysis

更新时间：2023-08-10

- Efficacy and safety of eltrombopag combined with immunosuppressive therapy in the treatment of severe aplastic anemia：a meta-analysis
- ZHONGGUO YAOFANG Vol. 34, Issue 15, Pages: 1891-1898(2023)
- 作者机构：
  
  1.郑州大学第一附属医院儿童血液肿瘤科，郑州　450052
  2.郑州大学第一附属医院小儿外科，郑州　450052
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.15.19
  CLC： R556.5;R969
- Published：15 August 2023，
  
  Received：15 December 2022，
  
  Revised：30 June 2023，
扫描看全文
李碧云,韩亚辉,殷楚云等.艾曲泊帕联合免疫抑制治疗对重型再生障碍性贫血的疗效和安全性的Meta分析 ^Δ[J].中国药房,2023,34(15):1891-1898.

LI Biyun,HAN Yahui,YIN Chuyun,et al.Efficacy and safety of eltrombopag combined with immunosuppressive therapy in the treatment of severe aplastic anemia：a meta-analysis[J].ZHONGGUO YAOFANG,2023,34(15):1891-1898.
李碧云,韩亚辉,殷楚云等.艾曲泊帕联合免疫抑制治疗对重型再生障碍性贫血的疗效和安全性的Meta分析 ^Δ[J].中国药房,2023,34(15):1891-1898. DOI： 10.6039/j.issn.1001-0408.2023.15.19.

LI Biyun,HAN Yahui,YIN Chuyun,et al.Efficacy and safety of eltrombopag combined with immunosuppressive therapy in the treatment of severe aplastic anemia：a meta-analysis[J].ZHONGGUO YAOFANG,2023,34(15):1891-1898. DOI： 10.6039/j.issn.1001-0408.2023.15.19.

摘要

目的

系统评价艾曲泊帕联合免疫抑制治疗（IST）对重型再生障碍性贫血（SAA）的疗效和安全性，为临床治疗SAA提供循证依据。

方法

系统检索PubMed、Embase、Cochrane Library、ClinicalTrials.gov、维普网、中国知网、万方数据库，检索时限为建库至2023年5月。收集艾曲泊帕联合IST（试验组）对比单纯IST（对照组）的随机对照试验（RCT）和队列研究，对纳入研究进行资料提取、质量评价（Cochrane手册 5.1.0）后，采用RevMan 5.4软件进行Meta分析、亚组分析、敏感性分析和发表偏倚分析。

结果

共纳入12项研究，共计1 344例患者。与对照组相比，试验组患者3个月时的客观缓解率（ORR）（RR＝1.34，95%CI为1.06～1.69，

＝0.01）及完全缓解率（CRR）（RR＝1.88，95%CI为1.31～2.71，

＝0.000 6）、6个月时的ORR（RR＝1.33，95%CI为1.23～1.43，

＜0.000 01）及CRR（RR＝1.88，95%CI为1.57～2.25，

＜0.000 01）均显著升高；而2组患者12个月时的ORR（RR＝0.99，95%CI为0.82～1.18，

＝0.88）、12个月时的CRR（RR＝1.02，95%CI为0.78～1.34，

＝0.87）、2年总生存率（HR＝0.61，95%CI为0.31～1.22，

＝0.17）、2年无事件生存率（HR＝0.81，95%CI为0.61～1.07，

＝0.14）、克隆进化率（RR＝1.01，95%CI为0.51～2.00，

＝0.98）和肝/肾功能不全、皮疹等不良反应的发生率比较，差异均无统计学意义（

＞0.05）。亚组分析结果显示，RCT和队列研究亚组中，试验组患者6个月时的ORR、6个月时的CRR均显著高于对照组（

＜0.05），而试验组患者的2年总生存率、2年无事件生存率、克隆进化率与对照组比较，差异均无统计学意义（

＞0.05）。敏感性分析和发表偏倚分析结果显示，本研究所得结果基本稳定且存在发表偏倚的可能性较小。

结论

在SAA的IST方案中添加艾曲泊帕可以提高患者早期血液学缓解率，对短期生存无明显影响，且不会增加不良反应和克隆进化的发生。

Abstract

OBJECTIVE

To systematically evaluate the efficacy and safety of eltrombopag combined with immunosuppressive therapy （IST） for severe aplastic anemia （SAA）， and to provide evidence-based basis for clinical treatment of SAA.

METHODS

Retrieved from PubMed， Embase， Cochrane Library， ClinicalTrials.gov， VIP， CNKI and Wanfang data， randomized controlled trials （RCTs） and cohort studies about eltrombopag combined with IST （trial group） versus IST alone （control group） were collected from the inception to May 2023. After data extraction and quality evaluation （Cochrane manual 5.1.0） of included studies， meta-analysis， subgroup analysis， sensitivity analysis and publication bias analysis were performed by using RevMan 5.4 software.

RESULTS

A total of 12 studies were screened， including 1 344 patients. Compared with control group， objective remission rate （ORR）（RR＝1.34， 95%CI was 1.06-1.69，

＝0.01） and complete response rate （CRR）（RR＝1.88， 95%CI was 1.31-2.71，

＝0.000 6） at 3 months， ORR （RR＝1.33，95%CI was 1.23-1.43，

＜0.000 01） and CRR （RR＝1.88，95%CI was 1.57-2.25，

＜0.000 01） at 6 months were significantly increased in trial group. There was no statistically significant difference between the two groups in ORR （RR＝0.99， 95%CI was 0.82-1.18，

＝0.88） and CRR （RR＝1.02， 95%CI was 0.78-1.34，

＝0.87） at 12 months， two-year overall survival （OS） rate （HR＝0.61， 95%CI was 0.31-1.22，

＝0.17）， two-year event-free survival （EFS） rate （HR＝0.81， 95%CI was 0.61-1.07，

＝0.14）， clone evolution rate（RR＝1.01， 95%CI was 0.51-2.00，

＝0.98） or the incidence of adverse drug reactions such as liver/renal insufficiency， rash （

＞0.05）. Results of subgroup analysis showed that ORR and CRR of trial group at 6 months were higher than those of the control group in RCT and the cohort study subgroups （

＜0.05）. There was no statistically significant difference in the two-year OS rate， two-year EFS rate or clone evolution rate between trial group and control group in the two subgroups （

＞0.05）. The results of sensitivity analysis and publication bias analysis showed that the results of this study were robust and the possibility of publication bias was small.

CONCLUSIONS

The addition of eltrombopag in the IST regimen of SAA can improve the early hematological remission rate of patients， has no significant impact on short-term survival， and will not increase the occurrence of adverse drug reactions and clonal evolution.

关键词

再生障碍性贫血艾曲泊帕免疫抑制治疗不良反应

Keywords

eltrombopagimmunosuppressive therapyadverse reaction

references

YOUNG N S. Aplastic anemia[J]. N Engl J Med，2018，379（17）：1643-1656.

SCHEINBERG P. Acquired severe aplastic anaemia：how medical therapy evolved in the 20th and 21st centuries[J]. Br J Haematol，2021，194（6）：954-969.

SCHEINBERG P，NUNEZ O，WU C，et al. Treatment of severe aplastic anaemia with combined immunosuppression：anti-thymocyte globulin，ciclosporin and mycophenolate mofetil[J]. Br J Haematol，2006，133（6）：606-611.

SCHEINBERG P，NUNEZ O，WEINSTEIN B，et al. Activity of alemtuzumab monotherapy in treatment-naive，relapsed，and refractory severe acquired aplastic anemia[J]. Blood，2012，119（2）：345-354.

SCHEINBERG P，TOWNSLEY D，DUMITRIU B，et al. Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution[J]. Blood，2014，124（18）：2820-2823.

FATTIZZO B，LEVATI G，CASSIN R，et al. Eltrombopag in immune thrombocytopenia，aplastic anemia，and myelodysplastic syndrome：from megakaryopoiesis to immunomodulation.[J] .Drugs，2019，79：1305-1319.

YOSHIHARA H，ARAI F，HOSOKAWA K，et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche[J]. Cell Stem Cell，2007，1（6）：685-697.

TOWNSLEY D M，SCHEINBERG P，WINKLER T，et al. Eltrombopag added to standard immunosuppression for aplastic anemia[J]. N Engl J Med，2017，376（16）：1540-1550.

ROSENFELD S，FOLLMANN D，NUNEZ O，et al. Antithymocyte globulin and cyclosporine for severe aplastic anemia：association between hematologic response and long-term outcome[J]. JAMA，2003，289：1130-1135.

PEFFAULT DE LATOUR R，KULASEKARARAJ A，IACOBELLI S，et al. Eltrombopag added to immunosuppression in severe aplastic anemia[J]. N Engl J Med，2022，386（1）：11-23.

ASSI R，GARCIA-MANERO G，RAVANDI F，et al. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia[J]. Cancer，2018，124（21）：4192-4201.

GORONKOVA O，NOVICHKOVA G，SALIMOVA T，et al. Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia[J]. Blood Adv，2023，7（6）：953-962.

ROZMAN C，NOMDEDEU B，MARIN P，et al. Criteria for severe aplastic anaemia[J]. Lancet，1987，330（8565）：955-957.

周支瑞，张天嵩，李博，等. 生存曲线中Meta分析适宜数据的提取与转换[J]. 中国循证心血管医学杂志，2014，6（3）：243-247.

TIERNEY J F，STEWART L A，GHERSI D，et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials，2007，8：16.

HIGGINS J P T，GREEN S. Cochrane handbook for systematic reviews of interventions：version 5.1.0[EB/OL]. （2011-03-20）[2020-10-06]. http：//handbook-5-1.cochrane.org/http://handbook-5-1.cochrane.org/.

STANG A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol，2010，25（9）：603-605.

FANG M X，SONG H，ZHANG J Y，et al. Efficacy and safety of immunosuppressive therapy with or without eltrombopag in pediatric patients with acquired aplastic anemia：a Chinese retrospective study[J]. Pediatr Hematol Oncol，2021，38（7）：633-646.

GROARKE E M，PATEL B A，GUTIERREZ-RODRIGUES F，et al. Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anaemia[J]. Br J Haematol，2021，192（3）：605-614.

JIE M，FU L L，LI S D，et al. Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children[J]. Pediatr Hematol Oncol，2021，38（7）：647-657.

JIN Y Y，LI R X，LIN S Y，et al. A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin-based IST in Chinese patients with severe aplastic anemia[J]. Ann Hematol，2022，101（11）：2413-2419.

LESMANA H，JACOBS T，BOALS M，et al. Eltrombopag in children with severe aplastic anemia[J]. Pediatr Blood Cancer，2021，68（8）：e29066.

ZAIMOKU Y，PATEL B A，SHALHOUB R，et al. Predic- ting response of severe aplastic anemia to immunosuppression combined with eltrombopag[J]. Haematologica，2022，107（1）：126-133.

张彦平，刘蒙蒙，展新荣，等. 免疫抑制联合艾曲泊帕治疗儿童重型再生障碍性贫血的疗效[J]. 中华实用儿科临床杂志，2022，37（5）：348-351.

杨讯，杨旭，许词，等. 艾曲波帕联合环孢素A对再生障碍性贫血患者血清血小板生成素、粒细胞集落刺激因子及粒-巨噬细胞集落刺激因子的影响[J]. 世界临床药物，2021，42（12）：1108-1112.

柴星星，李瑞鑫，杜晓鹏，等. 艾曲泊帕联合强化免疫治疗老年重型再生障碍性贫血35例分析[J]. 中国实用内科杂志，2021，41（4）：301-305.

WANG L，LIU H. Pathogenesis of aplastic anemia[J]. Hematology，2019，24（1）：559-566.

URBANOWICZ I，NAHACZEWSKA W，CELUCH B. Narrative review of aplastic anemia：the importance of supportive treatment[J]. Ann Palliat Med，2021，10（1）：694-699.

杨洁茹，王化泉，邵宗鸿. 艾曲泊帕治疗再生障碍性贫血作用机制的研究进展 [J] .中华医学杂志，2020，100（32）：2557-2560.

BABUSHK D V，Eltrombopag：a springboard to early responses in SAA[J] .Blood，2022，139：1-2.

KILLICK S B，BOWN N，CAVENAGH J，et al. Guidelines for the diagnosis and management of adult aplastic anaemia[J]. Br J Haematol，2016，172（2）：187-207.

ALVARADO L J，HUNTSMAN H D，CHENG H，et al. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ[J]. Blood，2019，133（19）：2043-2055.

TICHELLI A， DE LATOUR R P， PASSWEG J， et al. Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine， with or without granulocyte colony-stimulating factor： a severe aplastic anemia working party trial from the European group of blood and marrow transplantation[J]. Haematologica，2020，105（5）：1223-1231.

PATEL B A，GROARKE E M，LOTTER J，et al. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag：a phase 2 study[J]. Blood，2022，139（1）：34-43.

GHANIMA W，COOPER N，RODEGHIERO F，et al. Thrombopoietin receptor agonists：ten years later[J]. Haematologica，2019，104（6）：1112-1123.

DESMOND R，TOWNSLEY D M，DUMITRIU B，et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug[J]. Blood，2014，123（12）：1818-1825.

MATSUDA A，IMADA K，OBARA N，et al. Dysmegakaryopoiesis and transient mild increase in bone marrow blasts in patients with aplastic anemia treated with eltrombopag may be signs of hematologic improvement and not portend clonal evolution[J]. Am J Clin Pathol，2022，158（5）：604-615.

GILREATH J，LO M，BUBALO J. Thrombopoietin receptor agonists （TPO-RAs）：drug class considerations for pharmacists[J]. Drugs，2021，81（11）：1285-1305.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research progress of chemotherapy-related diarrhea induced by molecularly targeted anti-tumor drugs

Safety of omalizumab in the treatment of children with allergic diseases

Efficacy of different enteral nutrition drugs for severe acute pancreatitis and their gastrointestinal tolerance

Retrospective analysis of coagulopathy in patients with severe renal insufficiency caused by tigecycline

Research progress on analgesic effect and adverse drug reactions of opioid receptor agonist-antagonists

Related Author

SUN Xuelin

ZHENG Li

LI Hongsheng

HU Xin

ZHANG Yatong

ZENG Na

LI Jie

SUN Huajun

Related Institution

Dept. of Pharmacy， China Aerospace Science & Industry Corporation Hospital

Dept. of Pharmacy， Beijing Hospital/National Geriatrics Center/Institute of Geriatrics， Chinese Academy of Medical Science

Dept. of Pharmacy， Shanghai Children’s Hospital， School of Medicine， Shanghai Jiao Tong University

Dept. of Pharmacy， Jiangsu Provincial People’s Hospital

Pancreatic Center， Jiangsu Provincial People’s Hospital

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰